PYCXF
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atroph… Read more
PYCXF (PYCXF) - Net Assets
Latest net assets as of June 2025: $170.01 Million USD
Based on the latest financial reports, PYCXF (PYCXF) has net assets worth $170.01 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($183.28 Million) and total liabilities ($13.27 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $170.01 Million |
| % of Total Assets | 92.76% |
| Annual Growth Rate | 61.69% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 88.74 |
PYCXF - Net Assets Trend (2022–2025)
This chart illustrates how PYCXF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for PYCXF (2022–2025)
The table below shows the annual net assets of PYCXF from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $170.01 Million | +109.75% |
| 2024-06-30 | $81.05 Million | +184.98% |
| 2023-06-30 | $28.44 Million | -29.25% |
| 2022-06-30 | $40.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to PYCXF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11081907500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $375.77 Million | 221.60% |
| Total Equity | $169.57 Million | 100.00% |
PYCXF Competitors by Market Cap
The table below lists competitors of PYCXF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Larvotto Resources Ltd
AU:LRV
|
$221.07 Million |
|
Cloudberry Clean Energy As
OL:CLOUD
|
$221.08 Million |
|
MO-BRUK S.A. ZY 10
F:1VX
|
$221.12 Million |
|
Telefónica Deutschland Holding AG
PINK:TELDF
|
$221.13 Million |
|
2CRSI S.A.
PA:AL2SI
|
$221.00 Million |
|
Grand Industrial Holding Co Ltd
SHE:000626
|
$221.00 Million |
|
BlackRock Technology and Private Equity Term Trust
NYSE:BTX
|
$221.00 Million |
|
Beijing HuaYuanYiTong Thermal Technology Co Ltd
SHE:002893
|
$220.99 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PYCXF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 80,495,652 to 169,573,623, a change of 89,077,971 (110.7%).
- Net loss of 50,304,679 reduced equity.
- Share repurchases of 6,802,435 reduced equity.
- New share issuances of 145,815,911 increased equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-50.30 Million | -29.67% |
| Share Repurchases | $6.80 Million | -4.01% |
| Share Issuances | $145.82 Million | +85.99% |
| Other Changes | $369.17K | +0.22% |
| Total Change | $- | 110.66% |
Book Value vs Market Value Analysis
This analysis compares PYCXF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.77x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.62x to 2.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | $0.12 | $0.81 | x |
| 2023-06-30 | $0.08 | $0.81 | x |
| 2024-06-30 | $0.17 | $0.81 | x |
| 2025-06-30 | $0.29 | $0.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PYCXF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.08x
- Recent ROE (-29.67%) is above the historical average (-48.47%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -35.23% | 0.00% | 0.00x | 1.15x | $-17.80 Million |
| 2023 | -82.12% | 0.00% | 0.00x | 1.34x | $-25.56 Million |
| 2024 | -46.87% | 0.00% | 0.00x | 1.13x | $-45.77 Million |
| 2025 | -29.67% | 0.00% | 0.00x | 1.08x | $-67.26 Million |
Industry Comparison
This section compares PYCXF's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PYCXF (PYCXF) | $170.01 Million | -35.23% | 0.08x | $221.01 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |